(以下内容从华福证券《医药生物行业特发性肺纤维化IPF:百亿市场潜力,建议关注伊非尼酮(东阳光长江药业)》研报附件原文摘录)投资要点:行情回顾:本周(2025年5月19日-2025年5月23日)中信医药指数上涨1.92%,跑赢沪深300指数2.1pct,在中信一级行业分类中排名第2位;2025年初至今中信医药生物板块指数上涨4.7%,跑赢沪深300指数6.0pct,在中信行业分类中排名第5位。本周...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.